MA41014A - Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique - Google Patents

Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique

Info

Publication number
MA41014A
MA41014A MA041014A MA41014A MA41014A MA 41014 A MA41014 A MA 41014A MA 041014 A MA041014 A MA 041014A MA 41014 A MA41014 A MA 41014A MA 41014 A MA41014 A MA 41014A
Authority
MA
Morocco
Prior art keywords
arylmethyl
carboxamides
het
heteroaryl
kallikrein inhibitors
Prior art date
Application number
MA041014A
Other languages
English (en)
Other versions
MA41014B1 (fr
Inventor
Rebecca Louise Davie
Hannah Joy Edwards
David Michael Evans
Simon Teanby Hodgson
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52349552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41014(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of MA41014A publication Critical patent/MA41014A/fr
Publication of MA41014B1 publication Critical patent/MA41014B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA41014A 2014-11-27 2015-11-26 Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique MA41014B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1421083.5A GB201421083D0 (en) 2014-11-27 2014-11-27 Enzyme inhibitors
PCT/GB2015/053615 WO2016083820A1 (fr) 2014-11-27 2015-11-26 Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique
EP15804210.1A EP3224256B1 (fr) 2014-11-27 2015-11-26 Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique

Publications (2)

Publication Number Publication Date
MA41014A true MA41014A (fr) 2017-10-04
MA41014B1 MA41014B1 (fr) 2019-09-30

Family

ID=52349552

Family Applications (3)

Application Number Title Priority Date Filing Date
MA52063A MA52063B1 (fr) 2014-11-27 2015-11-26 Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA41014A MA41014B1 (fr) 2014-11-27 2015-11-26 Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique
MA47217A MA47217B1 (fr) 2014-11-27 2015-11-26 Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA52063A MA52063B1 (fr) 2014-11-27 2015-11-26 Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA47217A MA47217B1 (fr) 2014-11-27 2015-11-26 Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique

Country Status (37)

Country Link
US (6) US10364238B2 (fr)
EP (4) EP4039681A1 (fr)
JP (4) JP6653702B2 (fr)
KR (2) KR102496404B1 (fr)
CN (2) CN110577519A (fr)
AR (2) AR102850A1 (fr)
AU (2) AU2015352193B2 (fr)
BR (1) BR112017010882B1 (fr)
CA (1) CA2967894C (fr)
CL (1) CL2017001362A1 (fr)
CO (1) CO2017006230A2 (fr)
CY (3) CY1122255T1 (fr)
DK (3) DK3556752T3 (fr)
EC (1) ECSP17039127A (fr)
ES (3) ES2745815T3 (fr)
GB (1) GB201421083D0 (fr)
HK (1) HK1244268A1 (fr)
HR (3) HRP20220314T1 (fr)
HU (3) HUE047425T2 (fr)
IL (2) IL278182B (fr)
LT (3) LT3224256T (fr)
MA (3) MA52063B1 (fr)
MD (3) MD3224256T2 (fr)
ME (1) ME03514B (fr)
MX (2) MX2020013038A (fr)
MY (1) MY176853A (fr)
NZ (1) NZ731945A (fr)
PH (1) PH12017500901A1 (fr)
PL (3) PL3567037T3 (fr)
PT (3) PT3224256T (fr)
RS (3) RS63155B1 (fr)
RU (1) RU2707870C2 (fr)
SG (2) SG10201907819WA (fr)
SI (3) SI3556752T1 (fr)
TW (2) TWI686383B (fr)
UA (1) UA123087C2 (fr)
WO (1) WO2016083820A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
HUE057106T2 (hu) 2015-10-01 2022-04-28 Biocryst Pharm Inc Humán plazma kallikrein gátlók
GB201609519D0 (en) * 2016-05-31 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
SG11201809922YA (en) * 2016-05-31 2018-12-28 Kalvista Pharmaceuticals Ltd Pyrazole derivatives as plasma kallikrein inhibitors
GB201609603D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
US11168080B2 (en) 2017-04-26 2021-11-09 Mitobridge, Inc. Dynamin-1-like protein inhibitors
GB201719882D0 (en) * 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof
WO2019106359A1 (fr) * 2017-11-29 2019-06-06 Kalvista Pharmaceuticals Limited Inhibiteurs d'enzymes
LT3716952T (lt) * 2017-11-29 2022-04-11 Kalvista Pharmaceuticals Limited Vaisto formos, apimančios plazmos kalikreino inhibitorių
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
EP3765459A1 (fr) 2018-03-13 2021-01-20 Shire Human Genetic Therapies, Inc. Imidazopyridines substituées en tant qu'inhibiteurs de la kallicréine plasmatique et leurs utilisations
CA3121202A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composes pyrrole et pyrazole et leurs procedes d'utilisation
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
EP4010333A1 (fr) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
CN114728962A (zh) 2019-09-18 2022-07-08 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
CN113004286B (zh) * 2019-12-20 2022-08-12 成都康弘药业集团股份有限公司 作为血浆激肽释放酶抑制剂的三环类化合物及其用途
TW202144331A (zh) * 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
EP4116299A4 (fr) * 2020-03-04 2024-03-27 Medshine Discovery Inc. Composé hétérocyclique
WO2022079446A1 (fr) 2020-10-15 2022-04-21 Kalvista Pharmaceuticals Limited Traitements de l'œdème de quincke
WO2022084693A1 (fr) 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Traitements de l'oedème de quincke
US20240122909A1 (en) 2021-02-09 2024-04-18 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023002219A1 (fr) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Traitements de l'angio-oedème héréditaire
WO2023185634A1 (fr) * 2022-03-30 2023-10-05 南京明德新药研发有限公司 Composé hétérocyclique utilisé comme inhibiteur de la kallicréine plasmatique
LT4288036T (lt) 2022-04-27 2024-09-25 Kalvista Pharmaceuticals Limited Farmacinės plazmos kalikreino inhibitoriaus formos
WO2024025907A1 (fr) * 2022-07-29 2024-02-01 Rezolute, Inc. Inhibiteurs de la kallicréine plasmatique
WO2024180100A1 (fr) 2023-02-27 2024-09-06 Kalvista Pharmaceuticals Limited Nouvelle forme solide d'un inhibiteur de la kallicréine plasmatique

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US7101878B1 (en) 1998-08-20 2006-09-05 Agouron Pharmaceuticals, Inc. Non-peptide GNRH agents, methods and intermediates for their preparation
CZ302788B6 (cs) 1999-04-15 2011-11-09 Bristol-Myers Squibb Company ´N-(2-Chlor-6-methylfenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolkarboxamid, jeho použití a farmaceutický prostredek s jeho obsahem
ES2281565T3 (es) 2001-10-26 2007-10-01 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Inhibidores de la integrasa de vih de tipo dihidroxipirimidina carboxamida.
DE60235114D1 (de) 2001-11-01 2010-03-04 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
CA2483159C (fr) 2002-04-26 2010-08-10 Eli Lilly And Company Derives de triazole en tant qu'antagonistes des recepteurs de la tachykinine
EP1426364A1 (fr) 2002-12-04 2004-06-09 Aventis Pharma Deutschland GmbH Dérivés d'imidazole comme inhibiteurs du facteur Xa
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
AU2004209456A1 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Quinoline-derived amide modulators of vanilloid VR1 receptor
CA2876822C (fr) 2003-08-27 2015-11-17 David Shima Polytherapie pour le traitement de troubles neovasculaires oculaires
TW200526588A (en) * 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
GB0403155D0 (en) 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
EP1568698A1 (fr) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Dérivés de pyrrole en tant qu'inhibiteurs du facteur xa
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
ES2367312T3 (es) 2004-09-03 2011-11-02 Yuhan Corporation DERIVADOS DE PIRROLO [3,2-c] PIRIDINA Y PROCESOS PARA LA PREPARACIÓN DE LOS MISMOS.
EP2500031A3 (fr) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions et procédés de traitement de la perméabilité vasculaire
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
KR101142363B1 (ko) 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007011328A1 (fr) 2005-07-14 2007-01-25 Jackson Kenneth A Procédé d’inhibition d’aiguille hypodermique après utilisation
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
GB0606876D0 (en) * 2006-04-05 2006-05-17 Glaxo Group Ltd Compounds
US20070258976A1 (en) 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
MX2009000117A (es) 2006-07-06 2009-01-23 Glaxo Group Ltd N-fenilmetil-5-oxo-prolin-2-amidas sustituidas como antagonistas de receptores p2x7 y sus metodos de uso.
CA2658523C (fr) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibiteurs de kallicreine plasmatique
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
RU2485114C2 (ru) 2006-12-29 2013-06-20 Эбботт Гмбх Унд Ко.Кг Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов
WO2008091692A2 (fr) 2007-01-25 2008-07-31 Joslin Diabetes Center, Inc. Procédés de diagnostic, de traitement et de prévention de la perméabilité vasculaire accrue
AU2008223351A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
SG179437A1 (en) 2007-03-30 2012-04-27 Sanofi Aventis Pyrimidine hydrazide compounds as pgds inhibitors
KR20090127435A (ko) 2007-04-03 2009-12-11 글락소 그룹 리미티드 Ｐ2ｘ7 조절제로서의 이미다졸리딘 카르복스아미드 유도체
EP2181097A1 (fr) 2007-07-26 2010-05-05 Syngeta Participations AG Nouveaux microbiocides
CA2696429A1 (fr) 2007-08-22 2009-02-26 Allergan, Inc. Composes pyrroliques ayant une activite agoniste de recepteur de sphingosine-1-phosphate ou une activite biologique antagoniste
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009083553A1 (fr) 2007-12-31 2009-07-09 Rheoscience A/S Composés azines en tant qu'activateurs de glucokinase
US8658685B2 (en) 2008-01-31 2014-02-25 Activesite Pharmaceuticals, Inc. Methods for treatment of kallikrein-related disorders
WO2009106980A2 (fr) 2008-02-29 2009-09-03 Pfizer Inc. Dérivés d'indazole
ATE543811T1 (de) 2008-03-13 2012-02-15 Bristol Myers Squibb Co Pyridazinderivate als faktor-xia-inhibitoren
SI2308838T1 (sl) 2008-07-08 2016-09-30 Daiichi Sankyo Company, Limited Dušik vsebujoča aromatska heterociklična spojina
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
EA201200917A1 (ru) 2009-12-18 2012-12-28 Эктивсайт Фармасьютикалз, Инк. Пролекарства ингибиторов плазменного калликреина
JP2011157349A (ja) 2010-01-07 2011-08-18 Daiichi Sankyo Co Ltd 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物
ES2569983T3 (es) 2010-01-28 2016-05-13 The Medicines Company (Leipzig) Gmbh Inhibidores de serinproteasa de tipo tripsina y su preparación y uso
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
ES2483802T3 (es) 2010-07-07 2014-08-07 The Medicines Company (Leipzig) Gmbh Inhibidores de serina proteasa
WO2012009009A2 (fr) 2010-07-14 2012-01-19 Addex Pharma S.A. Nouveaux dérivés de 2-amino-4-pyrazolyl-thiazole et leur utilisation en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
EP2458315B1 (fr) 2010-11-25 2017-01-04 Balcke-Dürr GmbH Echangeur thermique régénératif doté d'un joint de rotor forcé
WO2012142308A1 (fr) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Promédicaments d'inhibiteurs de la kallicréine plasmatique
US9133128B2 (en) 2011-06-17 2015-09-15 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
WO2013048982A1 (fr) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Composés de pyrrolinone-carboxamide utiles en tant qu'inhibiteurs de lipase endothéliale
EP2760828B1 (fr) 2011-09-27 2015-10-21 Bristol-Myers Squibb Company Composés de pyrrolinone-carboxamide utiles en tant qu'inhibiteurs de lipase endothéliale
WO2013111108A1 (fr) * 2012-01-27 2013-08-01 Novartis Ag Dérivés hétéroarylcarboxamide à 5 chaînons comme inhibiteurs de la kallikréine plasmatique
EP2807156A1 (fr) 2012-01-27 2014-12-03 Novartis AG Dérivés d'aminopyridine utilisés en tant qu'inhibiteurs de la kallicréine plasmatique
CA2862289C (fr) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification par methylation, leurs compositions et utilisations
WO2013130603A1 (fr) 2012-02-27 2013-09-06 Board Of Regents, The University Of Texas System Ganglioside gd2 en tant que marqueur et cible sur des cellules souches cancéreuses
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
EP2943495B1 (fr) 2013-01-08 2016-12-28 Savira Pharmaceuticals GmbH Dérivés de pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
LT2948479T (lt) 2013-01-20 2018-11-26 Dyax Corp. Bradikinino sąlygotų sutrikimų įvertinimas ir gydymas
BR112015022340A2 (pt) 2013-03-15 2017-07-18 Verseon Corp método para tratamento ou prevenção de uma doença ou distúrbio relacionado à calicreína em um sujeito, composto, e, composição farmacêutica
WO2014188211A1 (fr) 2013-05-23 2014-11-27 Kalvista Pharmaceuticals Limited Dérivés hétérocycliques
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
CN105683179B (zh) 2013-08-14 2018-10-26 卡尔维斯塔制药有限公司 血浆激肽释放酶的抑制剂
EA032713B1 (ru) 2013-12-30 2019-07-31 Лайфсай Фармасьютикалс, Инк. Терапевтические ингибирующие соединения
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
MA53399B1 (fr) 2014-03-07 2022-10-31 Biocryst Pharm Inc Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
WO2015171527A1 (fr) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Pyrazolopyridine, pyrazolopyrimidine et composés apparentés
WO2015171526A2 (fr) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Composés de pyrazolopyridine tricycliques
EP3169325B1 (fr) 2014-07-16 2021-04-28 Attune Pharmaceuticals, Inc. Composés inhibiteurs thérapeutiques
EP3182962B1 (fr) 2014-08-22 2023-06-07 Biocryst Pharmaceuticals, Inc. Compositions et utilisations de dérivés d'amidine
AU2015317522A1 (en) 2014-09-17 2017-03-23 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
MX2017011000A (es) 2015-02-27 2017-10-20 Verseon Corp Compuestos de pirazol sustituidos como inhibidores de serina proteasa.
EP3317241A4 (fr) 2015-07-01 2019-01-23 Lifesci Pharmaceuticals, Inc. Composés inhibiteurs thérapeutiques
WO2017001926A2 (fr) 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc Composés inhibiteurs thérapeutiques
JP6855477B2 (ja) 2015-10-27 2021-04-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体
US10399961B2 (en) 2015-10-27 2019-09-03 Boehringer Ingelheim International Gmbh Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
SG11201809922YA (en) 2016-05-31 2018-12-28 Kalvista Pharmaceuticals Ltd Pyrazole derivatives as plasma kallikrein inhibitors
GB201609519D0 (en) 2016-05-31 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609602D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
EP3481391A4 (fr) 2016-07-11 2020-03-11 Lifesci Pharmaceuticals, Inc. Composés inhibiteurs thérapeutiques
GB201719882D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2019106359A1 (fr) 2017-11-29 2019-06-06 Kalvista Pharmaceuticals Limited Inhibiteurs d'enzymes

Also Published As

Publication number Publication date
GB201421083D0 (en) 2015-01-14
WO2016083820A1 (fr) 2016-06-02
EP3224256A1 (fr) 2017-10-04
IL278182A (en) 2020-11-30
AU2019240616B2 (en) 2021-07-29
CO2017006230A2 (es) 2017-09-11
MX2017006823A (es) 2017-09-27
ES2908303T3 (es) 2022-04-28
KR20170090451A (ko) 2017-08-07
ES2858082T3 (es) 2021-09-29
SG10201907819WA (en) 2019-09-27
EP3567037A1 (fr) 2019-11-13
EP3567037B1 (fr) 2020-12-23
MA52063A (fr) 2021-05-26
EP4039681A1 (fr) 2022-08-10
BR112017010882B8 (pt) 2023-10-31
SI3567037T1 (sl) 2021-04-30
AU2015352193A1 (en) 2017-06-08
RU2017122364A (ru) 2018-12-27
AR121273A2 (es) 2022-05-04
RS61497B1 (sr) 2021-03-31
ECSP17039127A (es) 2017-12-01
TWI686383B (zh) 2020-03-01
CA2967894C (fr) 2024-01-30
RS59395B1 (sr) 2019-11-29
RS63155B1 (sr) 2022-05-31
CY1125214T1 (el) 2023-06-09
TWI741377B (zh) 2021-10-01
CY1122255T1 (el) 2020-11-25
MD3556752T2 (ro) 2022-07-31
NZ731945A (en) 2021-07-30
MD3224256T2 (ro) 2019-12-31
PL3567037T3 (pl) 2021-06-14
MA47217B1 (fr) 2021-04-30
MA41014B1 (fr) 2019-09-30
DK3567037T3 (da) 2021-02-08
JP2020033357A (ja) 2020-03-05
HRP20220314T1 (hr) 2022-05-13
US10611758B2 (en) 2020-04-07
AR102850A1 (es) 2017-03-29
RU2017122364A3 (fr) 2019-06-19
HRP20191524T1 (hr) 2019-11-29
DK3224256T3 (da) 2019-09-23
CY1124046T1 (el) 2022-05-27
EP3556752B1 (fr) 2022-01-05
US20200361923A1 (en) 2020-11-19
CL2017001362A1 (es) 2018-02-09
TW201625548A (zh) 2016-07-16
IL252287B (en) 2020-11-30
RU2707870C2 (ru) 2019-12-02
US11198691B2 (en) 2021-12-14
KR102496404B1 (ko) 2023-02-06
HK1244268A1 (zh) 2018-08-03
CA2967894A1 (fr) 2016-06-02
KR102267623B1 (ko) 2021-06-18
NZ770256A (en) 2021-11-26
HUE047425T2 (hu) 2020-04-28
AU2019240616A1 (en) 2019-10-17
PT3567037T (pt) 2021-02-23
EP3224256B1 (fr) 2019-07-03
MX2020013038A (es) 2022-12-09
RU2019131174A (ru) 2019-10-10
JP6653702B2 (ja) 2020-02-26
MA52063B1 (fr) 2022-01-31
PL3224256T3 (pl) 2020-01-31
SI3224256T1 (sl) 2019-12-31
DK3556752T3 (da) 2022-03-07
EP3556752A1 (fr) 2019-10-23
US20220289729A1 (en) 2022-09-15
MD3567037T2 (ro) 2021-05-31
PT3556752T (pt) 2022-04-14
LT3224256T (lt) 2019-09-25
HUE057647T2 (hu) 2022-05-28
AU2015352193B2 (en) 2019-10-10
ES2745815T3 (es) 2020-03-03
BR112017010882B1 (pt) 2023-10-31
US11084809B2 (en) 2021-08-10
US20180319782A1 (en) 2018-11-08
CN107108576B (zh) 2020-03-10
LT3567037T (lt) 2021-02-25
US20190300517A1 (en) 2019-10-03
UA123087C2 (uk) 2021-02-17
JP2022180520A (ja) 2022-12-06
CN110577519A (zh) 2019-12-17
US20190330200A1 (en) 2019-10-31
HUE053317T2 (hu) 2021-06-28
KR20210075227A (ko) 2021-06-22
PT3224256T (pt) 2019-09-23
HRP20210350T1 (hr) 2021-04-16
PL3556752T3 (pl) 2022-05-02
JP2021185138A (ja) 2021-12-09
IL278182B (en) 2022-09-01
SI3556752T1 (sl) 2022-05-31
JP7148683B2 (ja) 2022-10-05
MY176853A (en) 2020-08-24
US20200199116A1 (en) 2020-06-25
JP6995101B2 (ja) 2022-01-14
MA47217A (fr) 2019-11-13
CN107108576A (zh) 2017-08-29
IL252287A0 (en) 2017-07-31
JP2017535568A (ja) 2017-11-30
US10364238B2 (en) 2019-07-30
SG11201703988PA (en) 2017-06-29
PH12017500901A1 (en) 2017-12-18
TW202026285A (zh) 2020-07-16
ME03514B (fr) 2020-04-20
US11001578B2 (en) 2021-05-11
LT3556752T (lt) 2022-03-10
BR112017010882A2 (pt) 2017-12-26

Similar Documents

Publication Publication Date Title
MA41014A (fr) Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique
IL287517A (en) Benzimidazole compounds as c-kit inhibitors
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
MA51229A (fr) Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr
MA53944A (fr) Inhibiteurs de la glycosidase
DK3466432T3 (da) Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
CL2016002638A1 (es) Nuevos inhibidores de la nitrificación
HUE057585T2 (hu) N-((het)arilmetil)-heteroaril-karboxamid vegyületek mint plazma kallikrein inhibitorok
DK3458460T3 (da) Imidazoler som histondemethylase-inhibitorer
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
DK3145536T3 (da) Modificeret tyrosinammoniaklyase
DK3224355T3 (da) Enzym-inhibitorkomplekser
ECSP17015682A (es) Inhibidores cristalinos de bace
TH1601003823B (th) ระบบจัดการงาน